menu
    • menu
    [{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Yarrow Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antisense Oligonucleotide Therapy","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Yarrow Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ Yarrow Biotechnology"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"ProQR Therapeutics","amount2":3.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":3.75,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"ProQR Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Rett Syndrome Research Trust","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Rett Syndrome Research Trust","highestDevelopmentStatusID":"3","companyTruncated":"ProQR Therapeutics \/ Rett Syndrome Research Trust"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AX-0810","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"QR-421a","moa":"USH2A","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"QR-421a","moa":"USH2A","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Technology","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"RSRT","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"AX-2402","moa":"MECP2","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ RSRT","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ RSRT"}]

    Find Clinical Drug Pipeline Developments & Deals by ProQR Therapeutics

    Menu

    ProQR Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AX-2402

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Sponsor : RSRT

                            Deal Size : $9.1 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ProQR Gets $8.1M from Rett Trust for RNA Editing Collaboration Expansion

                            Details : The collaboration will focus on designing and developing AX-2402, a Methyl CpG Binding Protein 2 (MECP2) therapy, for the treatment of Rett syndrome.

                            Product Name : AX-2402

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : AX-2402

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Sponsor : RSRT

                            Deal Size : $9.1 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Evercore ISI

                            Deal Size : $63.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

                            Details : The net proceeds from the offering will primarily be used to fund the advancement of current or future product candidates, including AX-0810 for the treatment of primary sclerosing cholangitis.

                            Product Name : AX-0810

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 25, 2024

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Evercore ISI

                            Deal Size : $63.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Evercore ISI

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

                            Details : The net proceeds from the offering will primarily be used to fund the advancement of current or future product candidates, including AX-0810 for the treatment of primary sclerosing cholangitis.

                            Product Name : AX-0810

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 22, 2024

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Evercore ISI

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Evercore ISI

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

                            Details : The net proceeds from the offering will primarily be used to fund the advancement of current or future product candidates, including AX-0810 for the treatment of primary sclerosing cholangitis.

                            Product Name : AX-0810

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 22, 2024

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Evercore ISI

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ProQR Announces Preclinical Proof Of Concept for AX-0810 RNA Editing Program

                            Details : AX-0810 is an editing oligonucleotide development program targeting SLC10A1 RNA, providing a controlled approach aimed at reducing bile acids concentration in the liver for cholestatic diseases.

                            Product Name : AX-0810

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 08, 2024

                            Lead Product(s) : AX-0810

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Sponsor : Rett Syndrome Research Trust

                            Deal Size : $1.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

                            Details : The collaboration focuses on developing editing oligonucleotides (EONs) using ProQR’s Axiomer technology to target MECP2 and correct specific mutations.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Sponsor : Rett Syndrome Research Trust

                            Deal Size : $1.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : Laboratoires Thea

                            Deal Size : $186.3 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic A...

                            Details : The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.

                            Product Name : QR-110

                            Product Type : Oligonucleotide

                            Upfront Cash : $8.6 million

                            December 08, 2023

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Laboratoires Thea

                            Deal Size : $186.3 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : Laboratoires Thea

                            Deal Size : $162.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ult...

                            Details : The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.

                            Product Name : QR-110

                            Product Type : Oligonucleotide

                            Upfront Cash : $13.7 million

                            August 01, 2023

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Laboratoires Thea

                            Deal Size : $162.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $3,750.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Lilly and ProQR to Expand RNA Editing Collaboration

                            Details : Under the terms of the expanded agreement, Lilly will gain access to additional targets in the central nervous system and peripheral nervous system with ProQR’s Axiomer platform.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : $75.0 million

                            December 22, 2022

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $3,750.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed

                            ProQR Therapeutics

                            Netherlands arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

                            Details : Following the results from the QR-110 (sepofarsen) Illuminate trial, the EMA has recommended an additional clinical trial be conducted for sepofarsen prior to submitting a Marketing Authorisation Application (MAA).

                            Product Name : QR-110

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 11, 2022

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth